Canada Markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
30.92-0.60 (-1.90%)
At close: 04:00PM EST
30.90 -0.02 (-0.06%)
After hours: 07:45PM EST

Cassava Sciences, Inc.

7801 North Capital of Texas Highway
Suite 260
Austin, TX 78731
United States
512 501 2444

Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Mr. Remi BarbierFounder, Chairman, Pres & CEO1.74M114.86k1960
Mr. Eric J. SchoenChief Financial Officer776.93kN/A1968
Dr. Nadav Friedmann M.D., Ph.D.Chief Medical Officer & Director765k251.29k1943
Dr. James W. Kupiec M.D.Chief Clinical Devel. Officer476.57kN/AN/A
Dr. George ThorntonSr. VP of TechnologyN/AN/AN/A
Mr. Michael ZamlootSr. VP of Technical OperationsN/AN/AN/A
Dr. Lindsay H. Burns Ph.D.Sr. VP of NeuroscienceN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Corporate Governance

Cassava Sciences, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.